Here in ESMO I was the discussant of two trials, one was for TIGIT and the other one was for the LAG-3. For the LAG-3 there was a phase III trial called RELATIVITY that compared the patients with carboplatin/nivolumab and the LAG-3 compound that is called [??] over chemotherapy immunotherapy. The trial didn’t show a benefit in the overall population but there was a benefit in the population of patients with PD-L1 more than 1%. Dr Girard, who presented the data, showed also some results of non-preplanned other subgroup analyses and there was a very favourable benefit in the population between 1-49% where the company will go and will do a clinical trial.

The other compound was the TIGIT and the TIGIT was the TIGIT of GSK. There was a multi-cohort trial with different doses of the TIGIT compound, belrestotug, it’s difficult to say. The trial showed a very good safety profile for multiple doses and clearly an increased activity when also the drug was increased with doses. That will go in a phase III trial with the combination of 400mg, which is an average between the toxicity and the activity, over pembrolizumab and over dostarlimab which is the backbone of the combination in PD-L1 more than 50%.

So there is a desperate research on finding new immune checkpoint inhibitors that is good research. We will see in the future if some of these trials will become positive.